These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17269176)

  • 1. Effect of ramipril on the incidence of diabetes.
    Epstein BJ; Cooper-DeHoff RM
    N Engl J Med; 2007 Feb; 356(5):523; author reply 523-4. PubMed ID: 17269176
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of ramipril on the incidence of diabetes.
    Potter BJ; LeLorier J
    N Engl J Med; 2007 Feb; 356(5):522-3; author reply 523-4. PubMed ID: 17274113
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of ramipril on the incidence of diabetes.
    Bangalore S; Messerli FH
    N Engl J Med; 2007 Feb; 356(5):522; author reply 523-4. PubMed ID: 17267916
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance--is there still hope?
    Ingelfinger JR; Solomon CG
    N Engl J Med; 2006 Oct; 355(15):1608-10. PubMed ID: 16980381
    [No Abstract]   [Full Text] [Related]  

  • 5. Blood pressure drug may prevent diabetes in some people.
    Mayo Clin Health Lett; 2002 Feb; 20(2):4. PubMed ID: 11965625
    [No Abstract]   [Full Text] [Related]  

  • 6. ACE inhibitors and high-risk patients.
    Myers KA
    CMAJ; 2000 Aug; 163(3):327. PubMed ID: 10951738
    [No Abstract]   [Full Text] [Related]  

  • 7. [Further options with ramipril. Besides cardio- and nephro-protection diabetes prevention, too?].
    MMW Fortschr Med; 2003 Sep; 145(39):47. PubMed ID: 14649075
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of ramipril on the incidence of diabetes.
    ; Bosch J; Yusuf S; Gerstein HC; Pogue J; Sheridan P; Dagenais G; Diaz R; Avezum A; Lanas F; Probstfield J; Fodor G; Holman RR
    N Engl J Med; 2006 Oct; 355(15):1551-62. PubMed ID: 16980380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DREAM study and its impact on India.
    Mohan V
    J Assoc Physicians India; 2006 Oct; 54():765-7. PubMed ID: 17214271
    [No Abstract]   [Full Text] [Related]  

  • 10. Ramipril and risk of diabetes.
    Potyk DK
    JAMA; 2002 Jan; 287(2):186; author reply 186-7. PubMed ID: 11779250
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
    ; Dagenais GR; Gerstein HC; Holman R; Budaj A; Escalante A; Hedner T; Keltai M; Lonn E; McFarlane S; McQueen M; Teo K; Sheridan P; Bosch J; Pogue J; Yusuf S
    Diabetes Care; 2008 May; 31(5):1007-14. PubMed ID: 18268075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramipril and risk of diabetes.
    Shlossberg AH
    JAMA; 2002 Jan; 287(2):186-7. PubMed ID: 11779251
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of ramipril on cardiovascular events in high-risk patients.
    Sharma AM; Pischon T; Engeli S
    N Engl J Med; 2000 Jul; 343(1):65; author reply 66. PubMed ID: 10896545
    [No Abstract]   [Full Text] [Related]  

  • 14. [Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)].
    Standl E; Nitschmann S
    Internist (Berl); 2007 Oct; 48(10):1173-6. PubMed ID: 17846732
    [No Abstract]   [Full Text] [Related]  

  • 15. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
    Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
    J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramipril: the better angiotensin-converting enzyme inhibitor?
    Gupta R
    Indian Heart J; 2008; 60(3):188-91. PubMed ID: 19240304
    [No Abstract]   [Full Text] [Related]  

  • 17. More than just hype.
    Shishkov W
    CMAJ; 2003 Jun; 168(13):1647; author reply 1647-8. PubMed ID: 12821617
    [No Abstract]   [Full Text] [Related]  

  • 18. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers.
    Spinar J; Vítovec J; Soucek M; Dusek L; Pavlík T;
    Vnitr Lek; 2009 May; 55(5):481-8. PubMed ID: 19514614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.
    Salehian O; Healey J; Stambler B; Alnemer K; Almerri K; Grover J; Bata I; Mann J; Matthew J; Pogue J; Yusuf S; Dagenais G; Lonn E;
    Am Heart J; 2007 Sep; 154(3):448-53. PubMed ID: 17719288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.
    Pasini AF; Garbin U; Nava MC; Stranieri C; Pellegrini M; Boccioletti V; Luchetta ML; Fabrizzi P; Lo Cascio V; Cominacini L
    Am J Hypertens; 2007 Apr; 20(4):443-50. PubMed ID: 17386354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.